JP2020526556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526556A5 JP2020526556A5 JP2020501316A JP2020501316A JP2020526556A5 JP 2020526556 A5 JP2020526556 A5 JP 2020526556A5 JP 2020501316 A JP2020501316 A JP 2020501316A JP 2020501316 A JP2020501316 A JP 2020501316A JP 2020526556 A5 JP2020526556 A5 JP 2020526556A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- carboxamide
- spiro
- oxy
- heptane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 267
- 125000003003 spiro group Chemical group 0.000 claims 121
- -1 carbocycle Chemical group 0.000 claims 104
- 125000000623 heterocyclic group Chemical group 0.000 claims 76
- 125000003545 alkoxy group Chemical group 0.000 claims 58
- 229910052799 carbon Inorganic materials 0.000 claims 50
- 229910052739 hydrogen Inorganic materials 0.000 claims 36
- 229910052736 halogen Inorganic materials 0.000 claims 29
- 150000002367 halogens Chemical class 0.000 claims 28
- 229910052760 oxygen Inorganic materials 0.000 claims 24
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 125000004432 carbon atom Chemical group C* 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- 229910004013 NO 2 Inorganic materials 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 10
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 claims 10
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 8
- RKVJYJJMGANCQJ-UHFFFAOYSA-N 7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carboxamide Chemical compound N1=C2C(=CC(=C1)C(=O)N)COCC2 RKVJYJJMGANCQJ-UHFFFAOYSA-N 0.000 claims 8
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 7
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 7
- JVOGPCAZHXALIS-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound C1=CC=CC2=C(C(=O)N)C=NN21 JVOGPCAZHXALIS-UHFFFAOYSA-N 0.000 claims 7
- PAQVSWFCADWSLB-UHFFFAOYSA-N 3-cyanobenzamide Chemical compound NC(=O)C1=CC=CC(C#N)=C1 PAQVSWFCADWSLB-UHFFFAOYSA-N 0.000 claims 6
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 5
- 150000002460 imidazoles Chemical class 0.000 claims 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 claims 5
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 4
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 4
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- 150000001345 alkine derivatives Chemical class 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- UHADCXYRFWNAIW-UHFFFAOYSA-N thieno[3,2-b]pyridine-6-carboxamide Chemical compound NC(=O)C1=CN=C2C=CSC2=C1 UHADCXYRFWNAIW-UHFFFAOYSA-N 0.000 claims 3
- DFZXAAHLJJRATO-UHFFFAOYSA-N 5-methyl-1-phenylpyrazole-4-carboxamide Chemical compound CC1=C(C(N)=O)C=NN1C1=CC=CC=C1 DFZXAAHLJJRATO-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
- GGNIKGLUPSHSBV-UHFFFAOYSA-N thiazole-5-carboxamide Chemical compound NC(=O)C1=CN=CS1 GGNIKGLUPSHSBV-UHFFFAOYSA-N 0.000 claims 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- DPYRAILBOJTIRV-UHFFFAOYSA-N 3-(cyanomethyl)benzamide Chemical compound NC(=O)C1=CC=CC(CC#N)=C1 DPYRAILBOJTIRV-UHFFFAOYSA-N 0.000 claims 1
- RRANUIMYSXUNCN-UHFFFAOYSA-N 3-(trifluoromethoxy)benzamide Chemical compound NC(=O)C1=CC=CC(OC(F)(F)F)=C1 RRANUIMYSXUNCN-UHFFFAOYSA-N 0.000 claims 1
- ZDUVDNJBASJKTP-UHFFFAOYSA-N 3-cyano-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C#N)=C1 ZDUVDNJBASJKTP-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- JKPXYSGFTYLPTJ-UHFFFAOYSA-N 4,4-difluorocyclohexane-1-carboxamide Chemical compound NC(=O)C1CCC(F)(F)CC1 JKPXYSGFTYLPTJ-UHFFFAOYSA-N 0.000 claims 1
- BMQQMYJYPCJWSY-UHFFFAOYSA-N 4-cyano-3-fluorobenzamide Chemical compound NC(=O)C1=CC=C(C#N)C(F)=C1 BMQQMYJYPCJWSY-UHFFFAOYSA-N 0.000 claims 1
- YKNAYZZTJKVZGH-UHFFFAOYSA-N 5-cyano-2-fluorobenzamide Chemical compound NC(=O)C1=CC(C#N)=CC=C1F YKNAYZZTJKVZGH-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- UPXWAHYAKKFNDN-UHFFFAOYSA-N 5-methyl-1-[4-(trifluoromethyl)phenyl]pyrazole-4-carboxamide Chemical compound CC1=C(C(N)=O)C=NN1C1=CC=C(C(F)(F)F)C=C1 UPXWAHYAKKFNDN-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- OAOJNTGCUVEIEL-UHFFFAOYSA-N 7,8-dihydro-5h-pyrano[4,3-b]pyridine Chemical compound C1=CC=C2COCCC2=N1 OAOJNTGCUVEIEL-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- YKKWRNSAVFZQQI-UHFFFAOYSA-N C(N)(=O)C=1C=C2C(=NC=1OC1CC3(CC(C3)NC(=O)C3CN(C(C3)=O)CC3=CC=C(C=C3)Cl)C1)C=CS2 Chemical compound C(N)(=O)C=1C=C2C(=NC=1OC1CC3(CC(C3)NC(=O)C3CN(C(C3)=O)CC3=CC=C(C=C3)Cl)C1)C=CS2 YKKWRNSAVFZQQI-UHFFFAOYSA-N 0.000 claims 1
- NBOSVFUFIWQIGM-UHFFFAOYSA-N C(N)(=O)C=1C=C2C(=NC=1OC1CC3(CC(C3)NC(=O)C=3N=C(SC=3)C3=CC=NC=C3)C1)N(N=C2C)C Chemical compound C(N)(=O)C=1C=C2C(=NC=1OC1CC3(CC(C3)NC(=O)C=3N=C(SC=3)C3=CC=NC=C3)C1)N(N=C2C)C NBOSVFUFIWQIGM-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- WDBQDZRKKFDOQF-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical compound C1=CC=CC2=C=C[N]N21 WDBQDZRKKFDOQF-UHFFFAOYSA-N 0.000 claims 1
- 102000000568 rho-Associated Kinases Human genes 0.000 claims 1
- 108010041788 rho-Associated Kinases Proteins 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 0 C*C1(CC(C)(*)C(C2)(*(C)CC(C)(CI(*)=I)C2(*C)*(*)[Rh])C(C)(C)C1)NC(CCCC(*)(*)CCCCC1)C1C1OC1[*+]C* Chemical compound C*C1(CC(C)(*)C(C2)(*(C)CC(C)(CI(*)=I)C2(*C)*(*)[Rh])C(C)(C)C1)NC(CCCC(*)(*)CCCCC1)C1C1OC1[*+]C* 0.000 description 3
- XVWYRVKVLNYXFA-UHFFFAOYSA-N CCN(C(C)=CC=C1)C1=O Chemical compound CCN(C(C)=CC=C1)C1=O XVWYRVKVLNYXFA-UHFFFAOYSA-N 0.000 description 1
- QRNMBYCPVJHTTJ-UHFFFAOYSA-N CCN(C)CCOCC Chemical compound CCN(C)CCOCC QRNMBYCPVJHTTJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531563P | 2017-07-12 | 2017-07-12 | |
| US62/531,563 | 2017-07-12 | ||
| PCT/US2018/041573 WO2019014308A1 (en) | 2017-07-12 | 2018-07-11 | 5-CHAIN AND BICYCLIC HETEROCYCLIC AMIDES AS ROCK INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526556A JP2020526556A (ja) | 2020-08-31 |
| JP2020526556A5 true JP2020526556A5 (enExample) | 2021-08-19 |
| JP7206252B2 JP7206252B2 (ja) | 2023-01-17 |
Family
ID=63036489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501316A Active JP7206252B2 (ja) | 2017-07-12 | 2018-07-11 | Ｒｏｃｋの阻害剤としての５員および二環式のヘテロ環アミド |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11078197B2 (enExample) |
| EP (1) | EP3652168B1 (enExample) |
| JP (1) | JP7206252B2 (enExample) |
| KR (1) | KR102680162B1 (enExample) |
| CN (1) | CN110869363B (enExample) |
| AR (1) | AR112273A1 (enExample) |
| AU (1) | AU2018300094A1 (enExample) |
| BR (1) | BR112020000284A2 (enExample) |
| CA (1) | CA3069311A1 (enExample) |
| CL (1) | CL2019003747A1 (enExample) |
| CO (1) | CO2019014455A2 (enExample) |
| EA (1) | EA202090256A1 (enExample) |
| ES (1) | ES2882432T3 (enExample) |
| IL (1) | IL271905B (enExample) |
| PE (1) | PE20200388A1 (enExample) |
| SG (1) | SG11201913236QA (enExample) |
| TW (1) | TW201908293A (enExample) |
| WO (1) | WO2019014308A1 (enExample) |
| ZA (1) | ZA202000877B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7113810B2 (ja) | 2016-07-07 | 2022-08-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのスピロラクタム |
| ES2829400T3 (es) | 2016-11-30 | 2021-05-31 | Bristol Myers Squibb Co | Inhibidores tricíclicos de Rho cinasa |
| EP3652164B1 (en) | 2017-07-12 | 2023-06-21 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
| US12060341B2 (en) | 2017-07-12 | 2024-08-13 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as ROCK inhibitors |
| ES2894128T3 (es) | 2017-07-12 | 2022-02-11 | Bristol Myers Squibb Co | Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca |
| TW201908293A (zh) * | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| WO2019014304A1 (en) | 2017-07-12 | 2019-01-17 | Bristol-Myers Squibb Company | SPIROHEPTANYL HYDANTOIDS AS ROCK INHIBITORS |
| EP3704121B1 (en) | 2017-11-03 | 2022-12-21 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
| CA3089527A1 (en) * | 2018-05-29 | 2019-12-05 | Fronthera U.S. Pharmaceuticals Llc | Autotaxin inhibitors and uses thereof |
| US10711000B2 (en) | 2018-05-29 | 2020-07-14 | Fronthera U.S. Pharmaceuticals Llc | Autotaxin inhibitors and uses thereof |
| US11248004B2 (en) | 2018-11-06 | 2022-02-15 | Cervello Therapeutics, Llc. | Substituted isoquinolines as rock kinase inhibitors |
| KR102882224B1 (ko) | 2018-11-06 | 2025-11-05 | 써벨로 테라퓨틱스, 엘엘씨 | Rock 키나아제 저해제 |
| MX2024001442A (es) | 2021-08-02 | 2024-02-27 | Syngenta Crop Protection Ag | Derivados de pirazol microbiocidas. |
| CN119110724A (zh) * | 2021-12-31 | 2024-12-10 | 哈佛大学校长及研究员协会 | 烟酰胺n-甲基转移酶的双环抑制剂、其组合物和用途 |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| AR131665A1 (es) | 2023-02-01 | 2025-04-16 | Syngenta Crop Protection Ag | Composiciones fungicidas |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025676A4 (en) * | 2006-06-08 | 2011-06-15 | Ube Industries | NEW INDAZONE DERIVATIVE WITH SPIRING STRUCTURE IN SIDE CHAIN |
| EP2068878B1 (en) | 2006-09-20 | 2019-04-10 | Aerie Pharmaceuticals, Inc. | Rho kinase inhibitors |
| CL2007003874A1 (es) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| EP2331507A2 (en) | 2008-09-18 | 2011-06-15 | Astellas Pharma Inc. | Heterocyclic carboxamide compounds |
| AU2011329233A1 (en) | 2010-11-15 | 2013-05-23 | Abbvie Deutschland Gmbh & Co Kg | NAMPT and ROCK inhibitors |
| TW201443023A (zh) | 2013-01-18 | 2014-11-16 | 必治妥美雅史谷比公司 | 作爲ｒｏｃｋ抑制劑之酞□酮及異喹啉酮 |
| TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物 |
| US9828345B2 (en) | 2013-02-28 | 2017-11-28 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors |
| WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物 |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| JP6633618B2 (ja) | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体 |
| CN107406426B (zh) | 2015-01-09 | 2020-11-20 | 百时美施贵宝公司 | 作为rock抑制剂的环状脲类 |
| EP3268360B1 (en) | 2015-03-09 | 2019-04-24 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| UY37073A (es) * | 2016-01-13 | 2017-07-31 | Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen |
| US10562887B2 (en) | 2016-05-27 | 2020-02-18 | Bristol-Myers Squibb Company | Triazolones and tetrazolones as inhibitors of ROCK |
| JP7155102B2 (ja) | 2016-07-07 | 2022-10-18 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素 |
| JP7113810B2 (ja) | 2016-07-07 | 2022-08-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのスピロラクタム |
| JP6903731B2 (ja) | 2016-07-07 | 2021-07-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力で選択的なｒｏｃｋ阻害剤としてのラクタム、環状尿素、およびカルバメート、およびトリアゾロン誘導体 |
| ES2829400T3 (es) | 2016-11-30 | 2021-05-31 | Bristol Myers Squibb Co | Inhibidores tricíclicos de Rho cinasa |
| EP3652164B1 (en) | 2017-07-12 | 2023-06-21 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
| WO2019014304A1 (en) | 2017-07-12 | 2019-01-17 | Bristol-Myers Squibb Company | SPIROHEPTANYL HYDANTOIDS AS ROCK INHIBITORS |
| TW201908293A (zh) * | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| ES2894128T3 (es) | 2017-07-12 | 2022-02-11 | Bristol Myers Squibb Co | Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca |
| EP3704121B1 (en) | 2017-11-03 | 2022-12-21 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
-
2018
- 2018-07-10 TW TW107123859A patent/TW201908293A/zh unknown
- 2018-07-11 PE PE2019002591A patent/PE20200388A1/es unknown
- 2018-07-11 IL IL271905A patent/IL271905B/en unknown
- 2018-07-11 US US16/629,717 patent/US11078197B2/en active Active
- 2018-07-11 JP JP2020501316A patent/JP7206252B2/ja active Active
- 2018-07-11 SG SG11201913236QA patent/SG11201913236QA/en unknown
- 2018-07-11 EA EA202090256A patent/EA202090256A1/ru unknown
- 2018-07-11 KR KR1020207003728A patent/KR102680162B1/ko active Active
- 2018-07-11 WO PCT/US2018/041573 patent/WO2019014308A1/en not_active Ceased
- 2018-07-11 AR ARP180101933 patent/AR112273A1/es unknown
- 2018-07-11 ES ES18746517T patent/ES2882432T3/es active Active
- 2018-07-11 CA CA3069311A patent/CA3069311A1/en active Pending
- 2018-07-11 EP EP18746517.4A patent/EP3652168B1/en active Active
- 2018-07-11 CN CN201880045773.8A patent/CN110869363B/zh active Active
- 2018-07-11 AU AU2018300094A patent/AU2018300094A1/en not_active Abandoned
- 2018-07-11 BR BR112020000284-4A patent/BR112020000284A2/pt not_active Application Discontinuation
-
2019
- 2019-12-19 CO CONC2019/0014455A patent/CO2019014455A2/es unknown
- 2019-12-19 CL CL2019003747A patent/CL2019003747A1/es unknown
-
2020
- 2020-02-11 ZA ZA2020/00877A patent/ZA202000877B/en unknown
-
2021
- 2021-06-17 US US17/349,980 patent/US11673886B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526556A5 (enExample) | ||
| JP2016519096A5 (enExample) | ||
| KR102583317B1 (ko) | Malt1 억제제로서의 피라졸 유도체 | |
| JP2020527560A5 (enExample) | ||
| DK2086972T3 (en) | CONNECTIONS MODULATING C-FMS AND / OR C-KIT ACTIVITY AND APPLICATIONS THEREOF | |
| JP4533534B2 (ja) | グリコーゲンシンターゼキナーゼ３のインヒビター | |
| JP6117235B2 (ja) | Ｐｉ３ｋの活性または機能の阻害剤の使用 | |
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| JP2018118992A5 (enExample) | ||
| JP2010513304A5 (enExample) | ||
| JP2014528479A5 (enExample) | ||
| JP2012532931A5 (enExample) | ||
| JP2020526547A5 (enExample) | ||
| JP2009519967A5 (enExample) | ||
| JP2013528591A5 (enExample) | ||
| JP2021501220A5 (enExample) | ||
| JP2017530960A5 (enExample) | ||
| RU2018123779A (ru) | Новые соединения | |
| RU2008110915A (ru) | Новые диазаспироалканы и их применение для лечения заболеваний, опосредованных ccr8 | |
| JP2013527173A5 (enExample) | ||
| AR102852A1 (es) | Inhibidores heterocíclicos de la calicreína plasmática | |
| JP2019537571A5 (enExample) | ||
| JP2016164184A5 (enExample) | ||
| JP2016516791A5 (enExample) | ||
| JP2012506848A5 (enExample) |